RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post

Commentary on Twitter

Venetoclax with obinutuzumab or rituximab as first-line treatment for pts with CLL & coexisting conditions has resulted in a large percentage of pts with undetectable minimal residual disease & long progression-free survival.

Read the Research Summary: https://t.co/2i45QN55Hz

— NEJM (@NEJM) May 14, 2023